%0 Journal Article
%A Bischof, Gérard N.
%A Brendel, Matthias
%A Barthel, Henryk
%A Theis, Hendrik
%A Barbe, Michael
%A Bartenstein, Peter
%A Claasen, Joseph
%A Danek, Adrian
%A Höglinger, Günter
%A Levin, Johannes
%A Marek, Ken
%A Neumaier, Bernd
%A Palleis, Carla
%A Patt, Marianne
%A Rullmann, Michael
%A Saur, Dorothee
%A Schroeter, Matthias L.
%A Seibyl, John
%A Song, Mengmeng
%A Stephens, Andrew
%A Sabri, Osama
%A Drzezga, Alexander
%A van Eimeren, Thilo
%T Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620
%J Journal of nuclear medicine
%V 65
%N 6
%@ 0097-9058
%C New York, NY
%I Soc.
%M FZJ-2024-05291
%P 952 - 955
%D 2024
%X We used a new data-driven methodology to identify a set of reference regions that enhanced the quantification of the SUV ratio of the second-generation tau tracer 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine ([18F]PI-2620) in a group of patients clinically diagnosed with 4-repeat tauopathy, specifically progressive supranuclear palsy or cortical basal syndrome. The study found that SUV ratios calculated using the identified reference regions (i.e., fusiform gyrus and crus-cerebellum) were significantly associated with symptom severity and disease duration. This establishes, for the first time to our knowledge, the suitability of [18F]PI-2620 for tracking disease progression in this 4-repeat disease population. This is an important step toward increased clinical utility, such as patient stratification and monitoring in disease-modifying treatment trials. Additionally, the applied methodology successfully optimized reference regions for automated detection of brain imaging tracers. This approach may also hold value for other brain imaging tracers.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 38575191
%U <Go to ISI:>//WOS:001251294600021
%R 10.2967/jnumed.123.265930
%U https://juser.fz-juelich.de/record/1030418